IGC Reports Financial Results for September 30, 2020 Quarter and Start of Phase 1 Cannabinoid Clinical Trial for Alzheimer's Patients - IGC Pharma, INC.

Press

Releases

November 23, 2020

IGC Reports Financial Results for September 30, 2020 Quarter and Start of Phase 1 Cannabinoid Clinical Trial for Alzheimer’s Patients

Related Posts

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer’s Disease

September 4, 2024

Recap of AAIC24 Conference Participation and Poster Presentations

August 28, 2024

IGC Announces Results of its 2024 Annual Stockholders Meeting

August 26, 2024

CEO Update

Recap of AAIC24 Conference Participation and Poster Presentations

August 28, 2024

Desk of CEO Marijuana Reclass

July 25, 2024